Perspectives for the pharmacological treatment of overactive bladder syndrome

It has been found that antimuscarinic drugs, viewed as the "gold standard" in overactive bladder syndrome (OAB) treatment, have an unsatisfactory tolerance profile and limited clinical effectiveness. This fact has given a clear impetus to search for new options in OAB pharmacotherapy. The...

Full description

Saved in:
Bibliographic Details
Published in:Ginekologia polska 2017-01, Vol.88 (9), p.504-508
Main Authors: Wróbel, Andrzej, Kluz, Tomasz, Surkont, Grzegorz, Wlaźlak, Edyta, Miotła, Paweł, Skorupska, Katarzyna, Rechberger, Tomasz
Format: Article
Language:English
Subjects:
Adrenergic beta-3 Receptor Agonists - therapeutic use
Anticonvulsants - therapeutic use
Antidepressive Agents - therapeutic use
Botulinum Toxins - therapeutic use
Calcitriol - analogs & derivatives
Female
Humans
Neurokinin-1 Receptor Antagonists - therapeutic use
Neurotoxins - therapeutic use
Receptors, Cannabinoid - drug effects
TRPV Cation Channels - antagonists & inhibitors
Urinary Bladder, Overactive - drug therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It has been found that antimuscarinic drugs, viewed as the "gold standard" in overactive bladder syndrome (OAB) treatment, have an unsatisfactory tolerance profile and limited clinical effectiveness. This fact has given a clear impetus to search for new options in OAB pharmacotherapy. The conducted pre-clinical trials have led to the development of new solutions for the treatment of OAB, which stand a good chance of being applied in clinical practice. The said compounds are characterised by higher receptor and organ specificity than currently used medications.
ISSN:0017-0011
2543-6767
DOI:10.5603/GP.a2017.0092